177Lu-PSMA I&T放射配体治疗与多西他赛化疗的肾毒性比较
这项回顾性多中心分析比较了145例接受177Lu-PSMA I&T治疗与39例接受多西他赛化疗的mCRPC患者的eGFR变化。结果显示,与多西他赛相比,177Lu-PSMA I&T与时间依赖性的肾功能逐渐下降相关,且12个月时严重eGFR下降(≥30%)更常见。研究提示应重视基线肾功能评估和纵向肾功能监测。
要点
- 177Lu-PSMA I&T较化疗更易导致eGFR随时间逐渐下降。
- 建议治疗前评估基线肾功能并纵向监测。
核心结论
- 与多西他赛化疗相比,177Lu-PSMA I&T与时间依赖性的肾功能逐渐下降相关,且不依赖既往化疗暴露和基线肾脏危险因素。
研究设计与样本
- 回顾性多中心分析纳入145例接受177Lu-PSMA I&T治疗和39例接受多西他赛化疗的mCRPC患者。
- 纳入要求≥4周期177Lu-PSMA I&T或≥10次多西他赛给药,且eGFR随访≥12个月。
- 按治疗顺序分层(仅多西他赛、化疗前和化疗后177Lu-PSMA I&T),采用线性混合模型评估纵向eGFR变化。
主要发现
- 化疗前和化疗后177Lu-PSMA I&T亚组平均eGFR随时间下降,与多西他赛组相比差异分别从3个月和12个月出现并持续至随访结束。
- 12个月时严重eGFR下降(≥30%)在177Lu-PSMA I&T组更常见:化疗前32.8% vs 2.6%(OR=18.5),化疗后31.0% vs 2.6%(OR=17.1),均p<0.001。
- 线性混合模型证实177Lu-PSMA I&T与多西他赛相比存在显著时间依赖性eGFR下降(整个队列β=-1.56;化疗前β=-1.41;均p<0.001)。
关键数值与推荐
- 严重eGFR下降定义为≥30%下降。
- 12个月时严重eGFR下降发生率:化疗前177Lu-PSMA I&T组32.8%,化疗后组31.0%,多西他赛组2.6%。
临床怎么用
- 对接受177Lu-PSMA I&T治疗的患者应进行基线肾功能评估和纵向肾功能监测。
- 在治疗疗程较早阶段考虑177Lu-PSMA RLT时尤需关注肾脏安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT: To compare changes in estimated glomerular filtration rate (eGFR) following Lutetium-177 prostate-specific membrane antigen I&T radioligand therapy (177Lu-PSMA I&T) and docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). METHODS: This retrospective multicenter analysis included 145 patients treated with 177Lu-PSMA I&T and 39 patients treated with docetaxel. Inclusion required ≥ 4 cycles of 177Lu-PSMA I&T or ≥ 10 docetaxel administrations and ≥ 12 months of eGFR follow-up. Docetaxel patients were excluded if 177Lu-PSMA I&T was initiated within 12 months after therapy initiation. Patients were stratified by treatment sequence (docetaxel only, pre-chemo and post-chemo 177Lu-PSMA I&T). Linear mixed models (LMM) assessed longitudinal eGFR changes with adjustment and matching for baseline renal risk factors (arterial hypertension, diabetes mellitus, age ≥ 65 years, prior platinum-based chemotherapy). RESULTS: Median age (interquartile range, IQR) was 75.0 (67.0–77.0) years in the docetaxel group, 81.5 (77.5–87.0) years in the pre-chemo 177Lu-PSMA I&T subgroup (n = 58), and 75.5 (71.0–78.3) years in the post-chemo 177Lu-PSMA I&T subgroup (n = 87). Mean eGFR declined over time in both pre- and post-chemo 177Lu-PSMA I&T subgroups compared with docetaxel-treated patients, with significant differences emerging earlier in the pre-chemo subgroup (from 3 months) and later in the post-chemo subgroup (from 12 months), persisting through follow-up. At 12 months, severe eGFR decline (≥ 30%) was more frequent after 177Lu-PSMA I&T than docetaxel (pre-chemo: 32.8% vs. 2.6%, OR = 18.5; post-chemo: 31.0% vs. 2.6%, OR = 17.1; both p < 0.001). LMM confirmed a significant time-dependent eGFR decline with ¹⁷⁷Lu-PSMA I&T versus docetaxel (entire cohort β=-1.56; pre-chemo β=-1.41; both p < 0.001). CONCLUSION: 177Lu-PSMA I&T is associated with a gradual, time-dependent decline in renal function compared with docetaxel, independent of prior chemotherapy exposure and baseline renal risk factors. These findings highlight the importance of baseline renal assessment and longitudinal kidney function monitoring, particularly as 177Lu-PSMA RLT is increasingly considered earlier in the treatment course.
引用
- Kirchhoff FP, Steinhelfer L, Pfob CH, et al. Assessment of nephrotoxicity following lutetium-177 PSMA I&T radioligand therapy: a comparative study with docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41986792. doi:10.1007/s00259-026-07890-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。